Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Total	At The Market Offering [Member]	Public Offering [Member]	Common Stock [Member]	Common Stock [Member] At The Market Offering [Member]	Common Stock [Member] Public Offering [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] At The Market Offering [Member]	Additional Paid-in Capital [Member] Public Offering [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2022	$ (107,900)			$ 94			$ 1,481,590			$ (3,590)	$ (1,585,994)
Beginning Balance, shares at Dec. 31, 2022				94,833,975
Exercise of stock options, value	14,319			$ 2			14,317
Exercise of stock options, shares				1,193,325
Vesting of restricted stock units, value	(1)			$ (1)
Vesting of restricted stock units, shares				721,216
Shares withheld related to net share settlement of equity awards	(10,517)						(10,517)
Shares withheld related to net share settlement of equity awards, shares				(262,829)
Issuance of common stock under Employee Stock Purchase Plan, value	4,140						4,140
Issuance of common stock under Employee Stock Purchase Plan, shares				136,065
Issuance of common stock, net of issuance costs, value		$ 164,233			$ 5			$ 164,228
Issuance of common stock, net of issuance costs, shares					5,016,170
Stock-based compensation	72,065						72,065
Unrealized (loss) gain on available-for-sale securities, net	3,600									3,600
Foreign currency translation adjustments	(20)									(20)
Net loss	(526,244)										(526,244)
Ending Balance at Dec. 31, 2023	(386,323)			$ 102			1,725,823			(10)	(2,112,238)
Ending Balance, shares at Dec. 31, 2023				101,637,922
Exercise of stock options, value	48,408			$ 3			48,405
Exercise of stock options, shares				2,425,991
Vesting of restricted stock units, shares				797,880
Shares withheld related to net share settlement of equity awards	(19,631)						(19,631)
Shares withheld related to net share settlement of equity awards, shares				(297,205)
Exercise of warrants, net, share				11,335
Conversion of 2026 Notes, share				151
Issuance of common stock upon private placement, value	50,000			$ 1			49,999
Issuance of common stock upon private placement, shares				980,392
Issuance of common stock under Employee Stock Purchase Plan, value	4,608						4,608
Issuance of common stock under Employee Stock Purchase Plan, shares				140,703
Issuance of common stock, net of issuance costs, value		$ 93,640	$ 563,204		$ 1	$ 11		$ 93,639	$ 563,193
Issuance of common stock, net of issuance costs, shares					1,237,460	11,274,510
Stock-based compensation	97,840						97,840
Unrealized (loss) gain on available-for-sale securities, net	2,153									2,153
Foreign currency translation adjustments	255									255
Net loss	(589,526)										(589,526)
Ending Balance at Dec. 31, 2024	(135,372)			$ 118			2,563,876			2,398	(2,701,764)
Ending Balance, shares at Dec. 31, 2024				118,209,139
Exercise of stock options, value	31,152			$ 2			31,150
Exercise of stock options, shares				1,551,261
Vesting of restricted stock units, value	(12)			$ (1)			(13)
Vesting of restricted stock units, shares				883,236
Shares withheld related to net share settlement of equity awards	(2,455)						(2,455)
Shares withheld related to net share settlement of equity awards, shares				(51,909)
Issuance of common stock under Employee Stock Purchase Plan, value	4,827						4,827
Issuance of common stock under Employee Stock Purchase Plan, shares				182,639
Induced conversion of convertible notes	116,672			$ 2			116,670
Induced conversion of convertible notes, shares				2,168,806
Stock-based compensation	112,286						112,286
Unrealized (loss) gain on available-for-sale securities, net	(990)									(990)
Foreign currency translation adjustments	(778)									(778)
Net loss	(784,955)										(784,955)
Ending Balance at Dec. 31, 2025	$ (659,625)			$ 123			$ 2,826,341			$ 630	$ (3,486,719)
Ending Balance, shares at Dec. 31, 2025				122,943,172

CYTOKINETICS INC 10-K